These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 21075464

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
    Luermans JG, Post MC, Schräder R, Sluysmans T, Vydt T, Vermeersch P, Chessa M, Onorato E, Goy JJ, Budts WI.
    Catheter Cardiovasc Interv; 2008 May 01; 71(6):822-8. PubMed ID: 18324695
    [Abstract] [Full Text] [Related]

  • 4. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
    Kutty S, Brown K, Asnes JD, Rhodes JF, Latson LA.
    Am J Cardiol; 2008 May 15; 101(10):1487-92. PubMed ID: 18471463
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Recurrence of cryptogenic stroke or TIA in patients with patent foramen ovale successfully treated by using different kind of percutaneous occluder devices: five-year follow-up.
    de Cillis E, Acquaviva T, Basile DP, Cipriani F, Bortone AS.
    Minerva Cardioangiol; 2010 Aug 15; 58(4):425-31. PubMed ID: 20938409
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
    Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Jüni P, PC Trial Investigators.
    N Engl J Med; 2013 Mar 21; 368(12):1083-91. PubMed ID: 23514285
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
    Ussia GP, Cammalleri V, Mulè M, Scarabelli M, Barbanti M, Scardaci F, Mangiafico S, Immè S, Capodanno D, Tamburino C.
    Catheter Cardiovasc Interv; 2009 Oct 01; 74(4):607-14. PubMed ID: 19360875
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
    Lehmann R, Fichtlscherer S, Baldauf H, Schächinger V, Auch-Schwelck W, Zeiher AM, Teupe C.
    J Cardiol; 2014 Aug 01; 64(2):113-6. PubMed ID: 24480741
    [Abstract] [Full Text] [Related]

  • 17. Clinical and brain magnetic resonance imaging follow-up after percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
    Vigna C, Inchingolo V, Giannatempo G, Pacilli MA, Di Viesti P, Fusilli S, Amico CM, Santoro T, Lanna P, Fanelli R, Simone P, Loperfido F.
    Am J Cardiol; 2008 Apr 01; 101(7):1051-5. PubMed ID: 18359330
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.